SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.

Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.

Positive

• Nasdaq extension granted until June 15, 2026
• Company meets other Nasdaq continued listing criteria
• Planned Phase 1 IV study completion for SCY-247

Negative

• Shares remain below the <$1.00 bid price requirement
• Possible reverse stock split could affect shareholder liquidity

Argus Dec 22 session

-2.31% close to close Open Argus

Details

News Market Reaction – SCYX

On Dec 22, the day this news came out, SCYX closed 2.31% below the previous close.

Data tracked by StockTitan Argus for the Dec 22 session.

Key Figures

Extension period: 180 calendar days Compliance deadline: June 15, 2026 Bid price requirement: $1.00 per share +5 more

Extension period

180 calendar days

Additional Nasdaq compliance window for minimum bid price

Compliance deadline

June 15, 2026

Date by which SCYX must regain $1.00 bid for 10 days

Bid price requirement

$1.00 per share

Nasdaq Listing Rule 5550(a)(2) minimum bid threshold

Consecutive days

10 business days

Duration closing bid must stay at or above $1.00

Phase 1 study

Phase 1

Planned IV formulation trial for SCY-247

Phase 2 data

Phase 2

Planned proof-of-concept oral SCY-247 in invasive candidiasis

Share price

$0.627

Price before news, below Nasdaq $1.00 threshold

52-week range

$0.565–$1.49

SCYX 52-week low and high before this announcement

Historical Context

5 past events · Latest: Nov 19

5 events

1. Nov 19

   NDA transfer update

   24h Move

   +1.8%

   Completion of BREXAFEMME NDA transfer to GSK with milestone potential.

2. Nov 17

   Collaboration funding

   24h Move

   -1.4%

   Federal grant supporting novel fungerp development via CETR collaboration.

3. Nov 05

   Earnings & update

   24h Move

   +0.1%

   Q3 2025 results, GSK payment, over two-year cash runway guidance.

4. Oct 15

   MARIO resolution

   24h Move

   -0.3%

   GSK agreement to terminate MARIO with payments and extended runway.

5. Sep 30

   Phase 1 results

   24h Move

   -26.7%

   Positive Phase 1 safety and PK data for second‑generation fungicide SCY-247.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, reverse stock split, intravenous (iv), phase 1, +3 more

7 terms

minimum bid price requirement regulatory

"to regain compliance with the minimum bid price requirement, as outlined in Nasdaq"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

reverse stock split financial

"intention to cure the deficiency within the extension period, if necessary, through a reverse stock split."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

intravenous (iv) medical

"complete a Phase 1 study of an intravenous (IV) formulation for our next-generation"

A method of delivering fluids, medicines or nutrients directly into a vein through a needle or tube so they enter the bloodstream immediately, like sending a package straight to the main highway instead of along side roads. Investors care because intravenous delivery affects how fast and reliably a treatment works, the complexity and cost of products and devices, hospital and clinic use, regulatory scrutiny and reimbursement — all of which influence commercial value.

phase 1 medical

"leverage our balance sheet to complete a Phase 1 study of an intravenous (IV)"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"as well as generate proof-of-concept Phase 2 data in the oral formulation"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

proof-of-concept technical

"as well as generate proof-of-concept Phase 2 data in the oral formulation"

A proof-of-concept is a demonstration that shows a new idea or method can work as intended, serving as a small-scale test before full development. For investors, it signals that a concept has been successfully tested in principle, reducing uncertainty about whether it can be practically implemented. This helps determine if further investment or effort is justified to develop the idea further.

investigational antifungal medical

"SCY-247 is an exciting investigational antifungal with the potential to benefit"

An investigational antifungal is a drug being developed to treat fungal infections that is still undergoing clinical testing and has not received regulatory approval for general use. Investors care because trial outcomes, safety data, and approval decisions determine whether the medicine can reach patients and earn revenue—similar to a prototype product being tested before launch, where successful tests increase potential value and setbacks can erase expected returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).

The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SCYNEXIS continues to meet all other continued listing criteria for the Nasdaq Capital Market, including the market value of publicly held shares, and has provided written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split.

“We are grateful for Nasdaq’s decision to grant this 180-day extension, which allows us to continue advancing our strategic objectives,” said David Angulo, M.D., President and Chief Executive Officer. “In the upcoming year we expect to leverage our balance sheet to complete a Phase 1 study of an intravenous (IV) formulation for our next-generation fungerp, SCY-247, as well as generate proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections. SCY-247 is an exciting investigational antifungal with the potential to benefit both hospitalized and community patients with challenging infections and is highly anticipated by the anti-infective scientific community. Lastly, SCYNEXIS remains committed to full compliance with all Nasdaq listing requirements and plans to take all necessary actions within the prescribed 180-day period to regain compliance.”

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME^® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: regaining Nasdaq compliance, completing a Phase 1 study of an IV formulation for SCY-247, generating proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections, and the potential benefits of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq action did SCYNEXIS (SCYX) receive on December 22, 2025?

SCYNEXIS received a 180-calendar-day extension to regain the minimum $1.00 bid-price compliance.

What is the deadline for SCYNEXIS (SCYX) to regain Nasdaq compliance?

The company has until June 15, 2026 to meet the $1.00 minimum bid price for 10 consecutive business days.

Will SCYNEXIS (SCYX) face delisting immediately after the extension?

No; Nasdaq granted an extension and confirmed SCYNEXIS meets other listing criteria while the cure period runs.

Could SCYNEXIS (SCYX) use a reverse stock split to regain compliance?

Yes; the company stated it may implement a reverse stock split within the extension period if necessary.

What clinical plans did SCYNEXIS announce for SCY-247 in 2026?

SCYNEXIS plans to complete a Phase 1 IV study and pursue proof-of-concept Phase 2 oral data for SCY-247.